1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsDARPA's Biological Technologies Office (BTO) seeks proposals for technologies focused at the intersection of artificial intelligence and biotechnology, aiming to catalyze future research projects and address national security challenges.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Offerors must submit white papers outlining their ideas. Selected proposals are awarded Research Other Transaction Agreements. Encourages first-time or non-traditional proposers. Confirm the full requirements in the official notice before applying.
The current listing shows up to $300,000 (for catalyst projects). Verify award ceilings, matching requirements, and allowable costs in the official notice.
AI Biotechnology Pitch Days is funded by Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Small Business Innovation Research (SBIR) Program Phase I (DOE Genesis Mission) is sponsored by U.S. Department of Energy (DOE) Office of Technology Commercialization (OTC). This DOE SBIR Phase I opportunity focuses on the Genesis Mission, supporting breakthrough technologies in areas including "Scaling the Biotechnology Revolution." Projects related to Pichia pastoris, particularly in areas of biotechnology for energy production, biomaterials, or sustainable processes, would be relevant. This is a pitch-first application process.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs (Genesis Mission Phase I) is sponsored by U.S. Department of Energy (DOE) Office of Technology Commercialization (OTC). This Phase I opportunity, focused on DOE's Genesis Mission, supports technologies in four areas including "Scaling the Biotechnology Revolution." Pichia pastoris is a significant host for biotechnology, particularly in the production of enzymes, biopharmaceuticals, and other biomolecules. Proposals advancing biotechnology, especially those with strong commercial potential and alignment with DOE mission areas, would be relevant.
FY2026 Phase I Genesis Mission Opportunity is sponsored by U.S. Department of Energy (DOE) Office of Technology Commercialization. This SBIR/STTR opportunity targets four AI-driven topic areas: biotechnology, quantum computing, materials design, and autonomous laboratories, supporting DOE's Genesis Mission. DOE intends to make approximately 40 awards totaling $10,000,000 for Phase I. The program requires a short Pitch application first; only companies invited after Pitch review can submit a full application.
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article